Pathological Complete Response from Pyrotinib Combined with Trastuzumab, Paclitaxel and Cisplatin in a Postpartum Woman with HER2-Positive Locally Advanced Breast Cancer: A Case Report

BACKGROUND: Overexpression of human epidermal growth factor receptor 2 (HER2) is associated with aggressive disease and poor prognosis. Traditional HER2-targeted agents can improve clinical outcome and have played an essential role in therapy. Pyrotinib is a newly irreversible tyrosine kinase inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Lina, Zhang, Fengchun, Ma, Yue, Zuo, Li, Xu, Yingchun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468538/
https://www.ncbi.nlm.nih.gov/pubmed/32943881
http://dx.doi.org/10.2147/OTT.S252117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468538/
https://www.ncbi.nlm.nih.gov/pubmed/32943881
http://dx.doi.org/10.2147/OTT.S252117

Ejemplares similares